DE

latest development

News & Events

London (UK) January 28th, 2025Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments. Vidac Pharma is thrilled to announce groundbreaking preclinical results demonstrating the synergistic potential of its proprietary compound, VDA1275, in combination with low concentrations of Cis-Platinum in a colorectal cancer animal model.

Following earlier findings showing synergy between VDA1275 and classical chemotherapeutic agents (Cis-Platinum and Sorafenib) in human liver cancer organoids, these results validate the compound’s efficacy across cancer types. This underscores the versatility of VDA1275, both as a standalone anti-cancer agent and as an enhancer of chemotherapy.

VDA1275 works by reversing the Warburg effect and resetting apoptosis while also modifying the tumor microenvironment (TME). This enables improved access for other treatments and better outcomes for patients.

The study, conducted by the contract research organization “Science in Action,” included six groups of 10 mice. The groups received various treatments, combining low-dose Cis-Platinum—known for its efficacy but also its challenging side effects—with VDA1275. The results were remarkable:

  • Median survival was extended from 26 days (untreated) to 45 days with the combined treatment, compared to 31 days with Cis-Platinum alone.
  • Tumor size reduction demonstrated a clear statistically significant  synergistic effect, with a 38.9% reduction after 38 days of combined treatment, compared to just 22.7% when results from adding the effect of Cis-Platinum alone and VDA1275 alone.

Dr. Max Herzberg, CEO of Vidac Pharma, expressed his enthusiasm:

“We are very excited by these findings. They pave the way for clinical studies in humans and offer the potential for reduced suffering and greater treatment effectiveness. Our mission is to put the ” patient  in mind” at the center of everything we do, both in Oncodermatology and in general Oncology and this breakthrough highlights our commitment to that principle. VDA1275 is a key to unlocking better use of chemotherapy through tumor microenvironment-modifying agents.”

Vidac Pharma products , already in Phase 2 in two oncodermatology pathologies  is dedicated to advancing innovative treatments for cancer and improving patient outcomes. These promising preclinical results mark a significant step toward achieving that goal.

For more information please contact:

Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/

investors@vidacpharma.com
+972-54-4257381

About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.

Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.